S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:GBIO

Generation Bio (GBIO) Stock Price, News & Analysis

$4.07
+0.37 (+10.00%)
(As of 03/28/2024 ET)
Today's Range
$3.72
$4.29
50-Day Range
$1.73
$4.07
52-Week Range
$0.86
$6.98
Volume
441,905 shs
Average Volume
271,247 shs
Market Capitalization
$270.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Generation Bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
96.6% Upside
$8.00 Price Target
Short Interest
Healthy
2.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Generation Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3,961 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.41) to ($1.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

240th out of 939 stocks

Pharmaceutical Preparations Industry

108th out of 444 stocks

GBIO stock logo

About Generation Bio Stock (NASDAQ:GBIO)

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO Stock Price History

GBIO Stock News Headlines

GBIO May 2024 7.500 call
GBIO Apr 2024 5.000 call
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Generation Bio Co (GBIO)
Generation Z: Page 4
Charles Rowland Bought 179% More Shares In Generation Bio
JMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)
See More Headlines
Receive GBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GBIO
Fax
N/A
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+96.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-126,610,000.00
Pretax Margin
-2,144.51%

Debt

Sales & Book Value

Annual Sales
$5.90 million
Book Value
$3.07 per share

Miscellaneous

Free Float
52,650,000
Market Cap
$270.57 million
Optionable
Optionable
Beta
2.70
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Cameron Geoffrey McDonough M.D. (Age 54)
    President, CEO & Director
    Comp: $939.09k
  • Dr. Matthew Norkunas M.B.A. (Age 45)
    M.D., Chief Financial Officer
    Comp: $611.11k
  • Dr. Matthew Stanton Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $654.83k
  • Dr. Mark D. Angelino Ph.D. (Age 51)
    Co-Founder
  • Dr. Robert Kotin Ph.D. (Age 68)
    Co-Founder
  • Ms. Antoinette Paone M.B.A. (Age 45)
    M.S., Chief Operating Officer
  • Ms. Yalonda Howze J.D. (Age 51)
    Chief Legal Officer & Secretary
  • Ms. Jasmin Tower
    Chief Human Resources Officer
  • Dr. Phillip Samayoa Ph.D. (Age 36)
    Chief Strategy Officer

GBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Generation Bio stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares.
View GBIO analyst ratings
or view top-rated stocks.

What is Generation Bio's stock price target for 2024?

6 brokerages have issued twelve-month price targets for Generation Bio's shares. Their GBIO share price targets range from $5.00 to $10.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 96.6% from the stock's current price.
View analysts price targets for GBIO
or view top-rated stocks among Wall Street analysts.

How have GBIO shares performed in 2024?

Generation Bio's stock was trading at $1.65 on January 1st, 2024. Since then, GBIO stock has increased by 146.7% and is now trading at $4.07.
View the best growth stocks for 2024 here
.

Are investors shorting Generation Bio?

Generation Bio saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 1,270,000 shares, a decrease of 11.8% from the February 29th total of 1,440,000 shares. Based on an average daily volume of 327,000 shares, the days-to-cover ratio is currently 3.9 days. Approximately 2.6% of the company's stock are short sold.
View Generation Bio's Short Interest
.

When is Generation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GBIO earnings forecast
.

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) released its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.12. The firm earned $2.88 million during the quarter, compared to the consensus estimate of $3.05 million.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

When did Generation Bio IPO?

Generation Bio (GBIO) raised $126 million in an initial public offering on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Generation Bio's major shareholders?

Generation Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.48%), Price T Rowe Associates Inc. MD (10.48%), Vanguard Group Inc. (3.86%), Vanguard Group Inc. (3.84%), PFM Health Sciences LP (2.46%) and Goldman Sachs Group Inc. (1.75%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas.
View institutional ownership trends
.

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GBIO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners